Hospital Admin Articles

Hospital Admin

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Trapp D - A recent Federal Trade Commission report asserting that original biopharmaceutical drug manufacturers do not need lengthy exclusive marketing periods to maintain innovation has not driven supporters from a bill that would extend such protection.

Related Articles

Nabi Biopharmaceuticals to Hold Conference Call
Nabi Biopharmaceuticals, 11/17/09    Relevance Score: 87%

Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
Bristol Myers-Squibb Company, 11/11/09    Relevance Score: 84%

Nabi Biopharmaceuticals Participates in NicVAX(R) Phase IIb Study
Nabi Biopharmaceuticals, 10/29/09    Relevance Score: 84%

Nabi Biopharmaceuticals to Announce Third Quarter Financial Results on November 2009
Nabi Biopharmaceuticals, 10/28/09    Relevance Score: 84%

Sanofi-aventis to acquire FOVEA, a French biopharmaceutical ophthalmology company
Sanofi-aventis, 10/02/09    Relevance Score: 84%

Today in Law/Ethics/Regulations...keeping you current

Ten reasons to oppose the criminalization of HIV exposure or transmission
Reproductive Health Matters, 12/14/09

Vertical HIV transmission should be excluded from criminal prosecution
Reproductive Health Matters, 12/14/09

More time to comply with Medicare enrollment policy
American Medical News , 12/11/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address